Mega Lifesciences Public Company Limited (SET: MEGA) has announced its 2021 consolidated financial statement through the Stock Exchange of Thailand as follows;
|Net Profit (Loss)
|Earning Per Share (Baht)||2.23||1.60|
MEGA reported a net profit of THB 1,946 million in 2021, increased by 39.79% from a net profit of THB 1,392 million in 2020. Growth in FY21 was mainly a result of growth in Mega We Care revenue and better gross margins.
Overall operating revenue in FY21 was THB 14,136mn, higher by 12.3% YoY. Mega We CareTM revenue was THB 6,909mn in FY21 (up by 18.2% YoY), while MaxxcareTM revenue was THB 6,906mn in FY21 (up by 6.2% YoY).
Overall gross margin in FY21 was 41.8% compared to 39.6% in FY20 and 43.3% in 4Q21 compared to 41.7% in 4Q20. Improvement in FY21 gross margin was mainly a result of growth in Mega We Care revenue, causing favourable revenue mix and better segmental gross margins. Mega We Care gross margins were healthier at 66.2% in FY21. Maxxcare gross margin was 17.5% in FY21 and the net margins (EBITDA/gross profits) for Maxxcare business was 48% in FY21 compared to 43.6% in FY20.
In addition, the Board of Directors approved a dividend payment of THB0.86 per share to be paid on 22 April 2022. The ex-dividend date is 8 March 2022.